Table 3.
Adverse events, by maximum grade reported
| Grade | Total (N = 32) | |||||
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | ||
| Hematologic AEs, n | ||||||
| Anemia | 0 | 4 | 5 | 1 | 0 | 10 |
| Thrombocytopenia | 0 | 3 | 4 | 3 | 0 | 10 |
| Neutropenia | 0 | 4 | 10 | 4 | 0 | 18 |
| Febrile neutropenia | 0 | 0 | 2 | 0 | 0 | 2 |
| Nonhematologic AEs, n | ||||||
| Diarrhea | 4 | 1 | 0 | 0 | 0 | 5 |
| Constipation | 6 | 0 | 0 | 0 | 0 | 6 |
| Nausea | 1 | 1 | 1 | 0 | 0 | 3 |
| Emesis | 0 | 1 | 1 | 0 | 0 | 2 |
| Fatigue | 5 | 9 | 1 | 0 | 0 | 15 |
| Dyspnea | 8 | 2 | 1 | 0 | 0 | 8 |
| Rash | 4 | 0 | 1 | 0 | 0 | 5 |
| Neuropathy/paresthesia | 6 | 1 | 0 | 0 | 0 | 6 |
| CHF | 0 | 0 | 1 | 0 | 0 | 1 |
| Muscle spasms | 4 | 2 | 0 | 0 | 0 | 6 |
| Transient ischemic attack | 0 | 0 | 1 | 0 | 0 | 1 |
| PE | 0 | 0 | 1 | 0 | 1 | 2 |
| DVT | 0 | 1 | 0 | 0 | 0 | 1 |
| Creatinine elevation | 5 | 4 | 1 | 2 | 0 | 12 |
| Skin infection | 2 | 0 | 1 | 0 | 0 | 3 |
| Pneumonia | 0 | 0 | 3 | 0 | 1 | 4 |
| Pneumonia parainfluenza viral | 2 | 0 | 0 | 0 | 0 | 1 |
| Upper respiratory tract infection | 1 | 0 | 0 | 0 | 0 | 1 |
| Alanine aminotransferase increased | 3 | 0 | 0 | 0 | 0 | 3 |
| Aspartate aminotransferase increased | 2 | 1 | 0 | 0 | 0 | 3 |
| Hyperbilirubinemia | 2 | 0 | 0 | 0 | 0 | 2 |
| Hypocalcemia | 2 | 3 | 0 | 0 | 0 | 5 |